These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25044253)

  • 1. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
    Krabbe LM; Svatek RS; Shariat SF; Messing E; Lotan Y
    Urol Oncol; 2015 Feb; 33(2):65.e19-25. PubMed ID: 25044253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Learning to Assess Long-term Mortality From Chest Radiographs.
    Lu MT; Ivanov A; Mayrhofer T; Hosny A; Aerts HJWL; Hoffmann U
    JAMA Netw Open; 2019 Jul; 2(7):e197416. PubMed ID: 31322692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
    Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
    Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants.
    Mir MC; Stephenson AJ; Grubb RL; Black A; Kibel AS; Izmirlian G
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2241-9. PubMed ID: 24089460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
    Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
    PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.
    Pinsky PF; Kramer BS
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26483244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heavy Cigarette Smoking and Aggressive Bladder Cancer at Initial Presentation.
    Pietzak EJ; Mucksavage P; Guzzo TJ; Malkowicz SB
    Urology; 2015 Nov; 86(5):968-72. PubMed ID: 26190088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
    Morales EE; Grill S; Svatek RS; Kaushik D; Thompson IM; Ankerst DP; Liss MA
    Eur Urol; 2016 Mar; 69(3):407-10. PubMed ID: 26320383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics of participants in the randomized national lung screening trial.
    ; Aberle DR; Adams AM; Berg CD; Clapp JD; Clingan KL; Gareen IF; Lynch DA; Marcus PM; Pinsky PF
    J Natl Cancer Inst; 2010 Dec; 102(23):1771-9. PubMed ID: 21119104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to general medical checkup and cancer screening guidelines according to self-reported smoking status: Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012.
    Kim EY; Shim YS; Kim YS; Lee SP; Ko KD; Choi WJ
    PLoS One; 2019; 14(10):e0224224. PubMed ID: 31639166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?
    Pinsky PF; Berg CD
    J Med Screen; 2012 Sep; 19(3):154-6. PubMed ID: 23060474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LINE1 methylation levels associated with increased bladder cancer risk in pre-diagnostic blood DNA among US (PLCO) and European (ATBC) cohort study participants.
    Andreotti G; Karami S; Pfeiffer RM; Hurwitz L; Liao LM; Weinstein SJ; Albanes D; Virtamo J; Silverman DT; Rothman N; Moore LE
    Epigenetics; 2014 Mar; 9(3):404-15. PubMed ID: 24316677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The National Lung Screening Trial Premise of Null and Chest Radiography Equivalence Is Open to Question.
    Reich JM; Kim JS
    AJR Am J Roentgenol; 2015 Aug; 205(2):278-9. PubMed ID: 26204275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
    Oken MM; Hocking WG; Kvale PA; Andriole GL; Buys SS; Church TR; Crawford ED; Fouad MN; Isaacs C; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Rathmell JM; Riley TL; Wright P; Caparaso N; Hu P; Izmirlian G; Pinsky PF; Prorok PC; Kramer BS; Miller AB; Gohagan JK; Berg CD;
    JAMA; 2011 Nov; 306(17):1865-73. PubMed ID: 22031728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.
    Kirsh VA; Hayes RB; Mayne ST; Chatterjee N; Subar AF; Dixon LB; Albanes D; Andriole GL; Urban DA; Peters U;
    J Natl Cancer Inst; 2006 Feb; 98(4):245-54. PubMed ID: 16478743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.